Brief: Relmada Gets FDA Support For Two Registrational Study Paths For NDV-01 In Non-Muscle Invasive Bladder Cancer
04/11/2025 12:46
Nov 4 (Reuters) - Relmada Therapeutics Inc RLMD.O: RELMADA ANNOUNCES FDA FEEDBACK SUPPORTING 2 SEPARATE ACCEPTABLE REGISTRATIONAL STUDY PATHS FOR NDV-01 IN NON-MUSCLE INVASIVE BLADDER CANCER RELMADA THERAPEUTICS INC - FDA CONFIRMS NO ADDITIONAL NON-CLINICAL STUDIES REQUIRED FOR NDV-01 RELMADA THERAPEUTICS INC - NDV-01 SHOWS 92% RESPONSE RATE IN NMIBC WITH GOOD SAFETY RELMADA THERAPEUTICS INC - SECURES FDA ALIGNMENT FOR PHASE 3 NDV-01 PROGRAM RELMADA THERAPEUTICS INC: INITIATING PHASE 3 PROGRAMS IN FIRST HALF OF 2026 Source text: ID:nGNX3786vB Further company coverage: RLMD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Relmada Therapeutics
See all newsRelmada Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Relmada Therapeutics Q2 EPS USD -0.11
Relmada Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia As Chief Business Officer
Brief: Relmada Therapeutics - Increases Authorized Common Stock To 200 Million Shares From 150 Million